Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-02 Motility stimulants
| Domperidone |
|
Formulary
|
Tablets 10mg
Suspension 1mg/ml
 To be commenced for this indication by GI and Critical Care specialists only.
Usually, the maximum treatment duration should not exceed one week. |
 MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects MHRA: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents MHRA: Domperidone: risks of cardiac side effects |
|
| Erythromycin |
|
Formulary
|
E/C Tablets 250mg
Oral suspension 125mg/5ml, 250mg/5ml
Intravenous infusion 1g
To be commenced for this indication by GI and Critical Care specialists only.
Prescriptions should include a review date. |
|
MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions |
|
|
| Metoclopramide |
|
Formulary
|
Tablets 10mg
Oral solution 5mg/5ml
To be commenced for this indication by GI and Critical Care specialists only.
Metoclopramide can induce acute dystonic reactions, these are more common in the young (especially girls and young women) and the very old.
Prescriptions should include a review date. |
|
MHRA: Metoclopramide: risk of neurological adverse effects |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Glycopyrronium Oral
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Dec 2017: Eluxadoline (Truberzi): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA: Domperidone: risks of cardiac side effects
- MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA: Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease
- MHRA: Metoclopramide: risk of neurological adverse effects
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
- NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea